Introduction Intrathecal chemotherapy is being explored in medulloblastoma in pre-school children as part of brainsparing strategies and as an alternative to unacceptably neurotoxic cranio-spinal radiotherapy. The range of drugs suitable for this route of administration is restricted by the lack of research evidence of pharmacological suitability and efficacy of other drugs in medulloblastoma. Methods Ideal clinical, biological, physicochemical and pharmaceutical properties for intrathecal administration were defined through literature review of pharmaceutical texts, Medline, Embase and consulting the manufacturers. A total of 126 chemotherapy agents were assessed against these criteria by searching the academic domain of pharmaceutical texts, computer databases and consultation with manufacturers. Results Of the 126 candidate drugs, 99 were rejected because of documentation of their irritant nature, neurotoxicity and requirement for hepatic activation in standard pharmaceutical texts. Fifty were rejected for a single identifiable reason including, neurotoxicity (n = 24), irritant (n = 15), needs enzyme activation (n = 5), clinical evidence of intrathecal neurotoxicity (n = 4) and no evidence of tumour-specific efficacy (n = 2). Where two reasons were cited the justifications were: neurotoxic and irritant (n = 3) and needs activation and systemic administration results in equivalent concentration (n = 1). Twenty-seven drugs remained of which 12 were selected as eligible for further clinical investigation, and 15 were selected for further pre-clinical investigation. Conclusions The pre-determined criteria were not applicable, in their entirety, in the majority of drugs, due to lack of information in the academic domain, emphasising the importance of a more open approach for sharing basic drug information. The prioritised list of 12 candidate drugs for clinical trial and 15 for pre-clinical investigation justify that a concerted research effort in this area of practice is made.
Introduction
Medulloblastoma, the commonest malignant CNS tumour of childhood [125] , has the capacity to disseminate through the lepto-meninges, presenting at diagnosis or at relapse after treatment. Leptomeningeal metastases (LM) grow at the interface of the brain and spinal fluid. They are thought to occur as a result of interplay between operative disruption of tumour cells contaminating the CSF and inherent biological capacity for tumour cells to migrate, adhere and invade neural tissue. Where LM are present at diagnosis biological factors are increasingly being associated with this dissemination and poorer cure rates with standard therapy. Systemic chemotherapy has an established role in medulloblastoma with evidence of chemosensitivity, enhanced survival rates and rising survival rates reported by trials groups and population registries [79] in the recent eras.
The use of intrathecal chemotherapy in childhood leukaemia and CNS tumours has been the focus of reviews [16, 48, 108] and reports of phase 1 and 2 studies [16] . In leukaemia, the intensification of systemic and intrathecal therapy has permitted exclusion of CNS radiotherapy for the majority of newly diagnosed cases with very low CNS relapse rates, acceptable late toxicity using methotrexate alone or in combination with cytosine and hydrocortisone. The intrathecal route in leukaemia has been demonstrated to bypass the blood brain barrier (BBB), enhance CSF drug concentrations reducing systemic exposure and, therefore, toxicity. Therefore, selection of drugs suitable for intrathecal administration and with evidence of sensitivity to primary CNS tumours is a challenge in medulloblastoma. Preliminary evidence of the efficacy of intrathecal therapy is emerging. Slavc [120, 121] reported extensive use of intrathecal therapy at relapse using etoposide, mafosfamide and others. Other studies report the feasibility of this route of drug administration at relapse and as part of palliative care with infrequent complications and prolonged symptom free intervals. Rutkowski [109] reported very high survival rates in pre-school children treated with chemotherapy-only strategy including intraventricular methotrexate. The proposal that intrathecal therapy be tested in a prospective European trial of medulloblastoma in this young age group is currently the focus of debate [139] .
In order to further develop an enhanced evidence base for the selection of drugs that are effective against medulloblastoma, suitable for administration by the intrathecal route, and non-toxic to the nervous system, we developed criteria for the ideal intrathecal agent. Following this a systematic literature review was conducted using these criteria to identify candidate drugs worthy of further trial for intrathecal use in medulloblastoma.
Method

Identification of candidate drugs
A comprehensive list of chemotherapy agents was extracted from a drug pharmacopoeia [86] . Properties of the ideal intrathecal drug were identified based upon the literature review [3, 9, 12, 32, 52, 101, 108, 132, 136, 143, 151, 152] and grouped according to: ''ideal clinical properties'', ''ideal biological properties'' and ''ideal physicochemical and pharmaceutical properties''.
Ideal clinical properties
Non-irritant
The drug would need to be non-irritant to avoid chemical arachnoiditis or meningitis. Any drug reported in any of our reference sources to cause irritation or thrombophlebitis was therefore eliminated from further consideration.
Neurotoxicity
Any drug given intrathecally has a significant risk of neurotoxicity. Evidence for neurotoxicity when given systemically or intrathecally was determined as an unacceptable risk for further evaluation of CSF administration. It was not possible to grade the neurotoxicities as they were variably reported. Some drugs which are not usually neurotoxic when given systemically at conventional doses, may be toxic if given intra-arterially, intrathecally or in very high doses [130] . Any drug reported in any of our reference sources to cause neurotoxicity was therefore eliminated from further consideration. Methotrexate and cytosine arabinoside, whilst suitable for IT delivery, have only been studied in medulloblastoma with concurrent systemic chemotherapy agents, the chemosensitivity of medulloblastoma to these drugs is, therefore, unknown.
Tumour sensitivity/mechanism of action Evidence of activity of the drug against medulloblastoma, PNET or leptomeningeal carcinomatosis is required to warrant further investigation. A drug with a mechanism of action effective at the CSF/leptomeningeal interface would offer a therapeutic advantage.
Methotrexate and cytosine arabinoside
Interestingly, the strict application of these criteria led to the exclusion of methotrexate and cytarabine (in its standard formulation) from the list of potential candidates. We are aware that these agents are commonly used intrathecally. The application of 'ideal criteria' which identifies lack of chemosensitivity data and substantial evidence of neurotoxicity led to their rejection from our ideal list, for the purposes of this review.
Ideal biological properties
CSF transport system
Some drugs are removed from the CSF by facilitated diffusion using carrier transport systems such as those for organic ions, quaternary ammonium compounds, organic bases and acids, also transporters conferring multi-drug resistance such as P-glycoprotein, multi-drug resistance protein 1, monocarboxylic acid and organic ion transporters [126] . The ideal intrathecal agent will have no active transport system that is capable of removing it from the CSF.
Cell cycle non-specific agent Cells in the process of dissemination may be in a noncycling, G o , or slow cycling phase. Drugs which act at specific stages of the cell cycle will need to be in contact with the cells for sufficient time for the cells to go through active cell division, to ensure an effective cell kill. An ideal agent would therefore be cell cycle non-specific in its action.
Ideal physicochemical and pharmaceutical properties
Active in CSF Drugs requiring enzyme activation (e.g. cyclophosphamide) are unlikely to be active since there are very few enzyme systems present in the CSF. Drugs administered in their active form or with predictable activation (e.g. hydrolysis) are proposed. Those requiring other processes of activation are excluded.
Factors affecting BBB permeability
Drugs in the CSF are likely to be in equilibrium with plasma as determined by the characteristics of the BBB and the drug's physical characteristics. Factors that reduce a drug's capacity to diffuse across the BBB and therefore limit drug efflux include: low lipophilicity, high hydrophilicity, ionised state at CSF pH of 7.3 and molecular weight [700 Da [52] . Such properties should therefore enhance sustained CSF drug levels and are therefore preferred for intrathecal therapy.
Protein binding
Ideally drugs normally protein bound are excluded. Direct injection to the CSF would overcome this and sustain their presence in CSF. This criteria has, however, not been used as the information was not available for the majority of drugs.
Formulation for CSF administration
The drug must be soluble in the appropriate concentration for intrathecal administration, and in a vehicle which is suitable for this route, including bio-compatibility with surgical delivery systems such as ventriculostomy reservoirs (Table 1) .
Literature search strategy and selection criteria
An initial search for the properties of each drug on the candidate list was undertaken by screening standard pharmaceutical texts [8, 29, 86] and by consulting the manufacturer. Some information was obtained from these sources. This permitted immediate elimination of a number of drugs due to evidence of irritancy, neurotoxicity and the need for liver enzyme activation. However, details of ionisation state and degree of protein binding for many drugs were unavailable despite direct approaches to manufacturers.
For the remaining drugs, Medline (1966-present) and Embase (1980-present) searches were performed. Each drug name was separately combined with the following terms: 'medulloblastoma', 'PNET' and 'leptomeningeal carcinomatosis', used in the 'exploded' form. Where hits exceeded 50 for a combination of terms, the search was further narrowed by combining that search with 'intrathecal administration'. The full text of papers with relevant abstracts was obtained and physicochemical information was extracted as well as:
• evidence of the drug's activity against medulloblastoma, PNET and leptomeningeal carcinomatosis in vitro and in vivo; • absence or presence of neurotoxicity reported from systemic or intrathecal administration; • documentation of intrathecal administration in vivo and in vitro. Tables 2, 3 ).
Rejected drugs
Of the 126 licensed and investigational anti-cancer chemotherapy agents identified, 99 drugs were excluded (Tables 2,  3 ). In 45 cases rejection was due solely to the lack of information. The remaining 54 drugs were rejected for a single reason (n = 50) or a combination of two reasons (n = 4).
Where a single reason is cited the justifications were: neurotoxicity (n = 24), irritant (n = 15), needs activation (n = 5), neurotoxic when given intrathecally (n = 4), lack of activity in relevant tumour type (n = 2). Where two reasons were cited, the justifications were: neurotoxic and irritant (n = 3), and needs activation and systemic administration results in equivalent concentration (n = 1).
Prioritised drugs for intrathecal use
From our initial list of 126 drugs, 12 drugs have been identified as suitable for further testing by the intrathecal route in medulloblastoma. Fifteen other potential candidates lack sufficient information to currently justify exploration of intrathecal administration, but warrant further research. The 27 drugs are therefore candidates for further testing via the intrathecal route focussed upon childhood medulloblastoma and other leptomeningeal malignancies. The most promising 12 drugs for PNET/medulloblastoma with prior reported clinical experience are detailed in Table 4 with justification of their potential for future research.
Evaluation in progress
Liposomal cytarabine and mafosfamide are currently undergoing phase 2 trials by the intrathecal route in children with brain tumours with leptomeningeal spread. Liposomal cytarabine has now been associated with significant neurotoxicity, particularly in adult patients also treated with systemic cytarabine [15] . It may be better tolerated in children. Comitant systemic corticosteroid treatment is recommended. Further studies are needed to establish optimal use of this drug.
These should be the first drugs to undergo further evaluation in phase 3 studies in order to further evaluate their efficacy and toxicity profiles and optimise dose and administration regimens.
Evaluation required in phase 2 trials
Carboplatin, etoposide, spartaject, busulfan and nimustine are agents suitable for treatment of PNET and are therefore also suitable for further investigation by the intrathecal route. Topotecan is undergoing intrathecal phase 2 studies in children and adults with refractory neoplastic meningitis; however, chemical arachnoiditis has been reported as a dose-limiting toxicity. Etoposide and nimustine have already been tested clinically with some encouraging results; however, refinement of drug delivery systems may be necessary to prolong exposure in order to overcome their rapid removal from the CSF, their currently observed efficacy may, therefore, be sub-optimal.
Phase 1 studies required
Floxuridine and 4-hydroperoxycyclophosphamide have been tested intrathecally in limited studies and have shown promise in relevant tumour types. The intrathecal use of these two agents should also be further explored.
Pre-clinical evaluation required
Diaziquone is lipophilic and has low ionisation at CSF pH. Together these physical properties suggest that it may not remain in the CSF unless delivered in a sustained release formulation or as an infusion. It is active in PNET and leptomeningeal carcinomatosis and has been used intrathecally in human studies. Mercaptopurine has been tested by the intraventricular route in animals and children with leptomeningeal dissemination of ALL but there is no evidence of efficacy in primary brain tumours. Rubitecan has been shown to be safe and effective in a rat model against human glioblastoma multiforme neoplastic meningitis.
Temozolomide is effective in medulloblastoma when given orally. A microcrystalline preparation has been used intrathecally in animal studies justifying further study if an appropriate formulation could be developed. Its lipophilicity would favour a sustained release formulation or an infusion
Pre-clinical animal evaluation
The nine drugs in Table 5 have documented activity in the relevant tumour types but no information was found on intrathecal use. These drugs would be worthy of intrathecal testing. The drugs in Table 6 have been tested in studies in the relevant tumour types by the intrathecal route (some animal, some human) with mixed reports of toxicity and efficacy. With the exception of bleomycin where neurotoxicity seems to be a major problem, these may well be worthy of further research. Carmustine is licensed in a sustained release preparation designed to be implanted into tumour resection cavities as an adjunct to surgery for GBM after relapse. However, it is documented also to have serious neurotoxicity when given systemically and therefore has not been prioritised in the list of drugs for further study.
Gemcitabine has been tested by the intrathecal route in a patient with leptomeningeal carcinomatosis from nonsmall cell lung cancer and has been used intrathecally in non-human primate models [34, 44, 66] . Based upon this, a phase 1 clinical trial of intrathecal gemcitabine has been conducted in ten patients with neoplastic meningitis including one with medulloblastoma. However, dose-limiting neurotoxicity was observed in patients who had previously received CNS-directed therapies [14] . The authors concluded that the potential for severe neurotoxicity precludes further development of gemcitabine for intrathecal administration.
Discussion
This work helps draw three important conclusions. First, many of the proposed ideal criteria, have not been applicable because of inadequate data in the academic and commercial information domains. A more open shared strategy between pharma and academic researchers of basic pharmacological data is required. Second, using supplementary clinical criteria, the systematic review has identified 12 drugs suitable for immediate intrathecal use in medulloblastoma, 15 other candidate drugs were identified for further evaluation prior to human use. Finally, the extended list of agents, identified here as suitable for intrathecal use, justifies further efforts to explore their role as part of brain-sparing strategies in clinical trials.
Ideal criteria
The pre-determined criteria were applicable in their entirety in only eight drugs resulting in the current drug selection being based primarily upon alternative criteria including: (a) clinical evidence of tumour chemo-sensitivity, (b) previously reported intrathecal use and (c) reported evidence of neurotoxicity after systemic or intrathecal administration. The overwhelming reason for rejection was because of either insufficient or inconsistent information in the academic domain (Tables 2, 3 ). It remains unclear why this basic physicochemical data are unavailable, highlighting the importance of promoting a more open ethic between pharma and academic groupings exploring novel applications of existing cancer drugs and in particular for intrathecal administration. This large category of known, rejected drugs as well as a presumed larger number of unknown candidate agents in industrial archives constitutes an untapped resource. In contrast, drugs with inconsistent data, but promising early laboratory or clinical evidence of suitability, are a group where further efforts for their evaluation are justified. Furthermore, as new biological agents are developed which affect tumour behaviour via non-cytotoxic mechanisms, the lack of publication of physicochemical criteria or clinical pharmacological data will slow down the process of their selection or rejection for intrathecal use.
Drug selection
From this review, 12 agents were identified as potentially suitable for human use. The three largest previous reviews Table 4 2. Cytarabine Table 4 3. Diaziquone Table 4 4. Etoposide Table 4 5. Floxuridine (FdUrd) Table 4 6. 4-Hydroperoxycyclophosphamide Table 4 7. Mafosfamide Table 4 8. Mercaptopurine Table 4 9. Nimustine (ACNU) Table 4 10. Temozolomide Table 4 11. Topotecan Table 4 12. Eflornithine Table 5 13. Mitolactol (Dibromodulcitol) Table 5 14. Didemnin B Table 5 15. Irinotecan Table 5 16.
Lomustine (CCNU) Table 5 17. Lonidamine Table 5 18. Menogaril Table 5 19. Tauromustine  Table 5 20. Teniposide Table 5 21. Busulphan Table 6 22. Carmustine (BCNU) Table 6 23. Dacarbazine Table 6 24. Fazarabine Table 6 25. Ranimustine (MCNU) Table 6 26. Zinostatin Table 6 of this treatment approach do specify optimal drug criteria for intrathecal use but do not specify the method by which they developed their proposed drug selections for intrathecal use (Table 7) . The current review has identified four additional drugs: carboplatin, floxuridine, 4-hydroperoxycyclophosphamide and rubitecan, yet rejected cytarabine (in its standard formulation) and methotrexate because of evidence of neurotoxicity. The extensive experience with these two latter drugs for prophylactic, therapeutic and palliative strategies in acute leukaemia and lymphoma has permitted comprehensive reporting of neurotoxicity. It has been proposed that enhanced and prolonged drug levels due to reduced permeability of the BBB arising from tumour involvement at sites of CSF efflux is a hypothesis for this observed effect [22, 23, 54, 85] . Carmustine in its wafer preparation (Gliadel TM ) is used for interstitial therapy for GBM at relapse. Prior reports of neurotoxicity after intraarterial administration might have excluded this drug. Its lipophilicity makes it unsuitable as an intrathecal agent without adaptation to its formulation to slow its release or as an infusion. Its current application within a sustained release wafer is, therefore, compatible with the 'ideal criteria' based upon physicochemical properties but not via the intrathecal route aimed at generalised CSF distribution.
Nine drugs were identified with evidence of efficacy against medulloblastoma but insufficient information about their suitability for intrathecal use (Table 5 ). More information about their physicochemical/cycle specific and neurotoxicity properties is required before they could be accepted/rejected for evaluation by the ideal criteria. The information that was missing was physicochemical (7), cell cycle specificity (4) and neurotoxicity (7) . The previous reviews [16, 48, 108] made no suggestions for this category of agents. Drugs, tested by the intrathecal route but with mixed reports of toxicity (n = 7; Table 6 ), were based upon clinical case reports from both animal and human experimentations, limiting the scope of this group as a source of new drugs for testing. There were conflicting reports of neurotoxicity. In only one drug was there a complete physicochemical dataset (dacarbazine). In three drugs (bleomycin, busulfan and carmustine) drug formulation was reported to influence neurotoxicity and efficacy. This group of drugs highlights the importance of selecting or developing drug formulations that maximise efficacy and minimise neurotoxicity.
Having identified a short list of 12 drugs suitable for human trial via the intrathecal route (Table 4 ) an attempt to select those suitable for immediate use has been made based upon currently available data. Carboplatin, etoposide and nimustine are identified as having the strongest evidence base for intrathecal use. Liposomal cytarabine (Depocyte) and mafosfamide are currently undergoing phase 2 trials; their efficacy and toxicity will need to be judged when given without comitant chemotherapy or radiotherapy. Mafosfamide is unlicensed and is therefore unavailable for clinical use in trial or therapy (Personal communication: Irene Slavc, irene.slavc@akh-wien.ac.at; Dr Susan Blaney, smblaney@txccc.org). Liposomal cytarabine (Depocyte) is being extensively investigated in adult studies in a variety of cancer types. Preliminary information has identified substantial evidence of neurotoxicity [64, 80] . In selecting any of these drugs for use, the more fat-soluble drugs will require either a pharmaceutical formulation aimed at prolonging drug release or the use of intrathecal infusions to sustain drug levels. Such infusional techniques are well developed for intrathecal baclofen aimed at controlling spasticity and could be adapted for such an application [123] .
Limitations
Our criteria for accepting or rejecting drugs were applied strictly, therefore. Any drug for which we found documentation of it being irritant or neurotoxic was rejected. It is possible that these criteria were applied too strictly since, for example, methotrexate and cytarabine (standard formulation) were excluded and liposomal cytarabine (Depocyte) has been accepted. Evidence of neurotoxicity of liposomal cytarabine is now emerging. However, the objective of the study was to identify drugs with ideal characteristics for intrathecal use.
It is difficult to interpret many studies of intrathecal chemotherapy in terms of efficacy, as in many cases simultaneous systemic chemotherapy or radiation, or both were administered along with intrathecal treatment making it unclear which component of therapy produced the effect. Most of the patients recruited into such studies are refractory to other treatments and are therefore undergoing such trials as a 'last resort'. In spite of this, measurable response to IT therapy, introduced after systemic chemotherapy has proved refractory, is reported as evidence of effect.
Drug administration
The clinical benefits of intrathecal administration need to be balanced against the risks relating to safe prescribing, clinical governance, technical and toxicity issues [37] . Furthermore, in contrast to leukaemia and lymphomas, primary CNS tumours represent anatomical challenges to drug distribution linked to the presence of ventrico peritoneal (VP) shunts, the influence of drainage of the third ventricle to basal cistern by neuroendoscopic third ventriculostomy, distortion of CNS anatomy linked to postresection tumour bed, post-operative incarceration of the posterior fossa and spinal blocks. Finally, the ideal timing of intrathecal administration in relation to debulking surgery is unclear. Such factors will clearly influence the distribution of CSF and any drug it carries. The challenges of drug delivery to the brain have resulted in a considerable volume of research, which may overcome some of these problems, through either local delivery approaches [105, 140] or vascular delivery across the BBB [56, 78, 103] . However, relatively little research has been focussed upon delivery systems for intrathecal delivery, the main example being that of liposomal cytarabine [21] . The role of efflux inhibitors such as valspodar in combination with intrathecal therapy in order to overcome the problems of removal of drugs from the CSF by multi-drug resistance transporters could also be explored [126] . The application of this method of drug administration in medulloblastoma is timely, as cure rates with combined chemo-radiotherapy for both localised and metastatic cases are improved ([70%, 5 years survival) in school age children. Novel biological markers are identifying patients with favourable tumour types where further de-escalation of neurotoxic cranial radiotherapy by adjustments to dose/ fractionation schedules or fields. The role of systemic chemotherapy, whilst established in this age group, will be further examined in trials focussing upon minimising toxicity.
In pre-school age children with favourable presentations (non-metastatic, completely resected, desmoplastic histology) survival rates also exceed 70% in the recently reported studies [53, 109] using both low-and highintensity chemotherapy schedules with or without intrathecal methotrexate and with or without involved field radiotherapy. The interaction between biological markers and these treatment strategies in this age group is yet to be studied [7, 57, 110] . The role of chemotherapy is, therefore, established. The potential for novel biological agents is yet to be explored but is anticipated.
Selecting drugs for IT trial
The most effective and safe way of delivering a drug to the leptomeningeal CSF interface will continue to be a challenge. In seeking to optimise drug delivery, drug selection is the first step. The route and method of administration will need to be studied further, i.e. the intraventricular route, the lumbar route, by bolus and by infusion. Anatomical factors will require consideration including the effects of tumour location, CSF circulation, including VP shunting and post-operative complications affecting the tumour bed. Once drugs have been tested in phase 1 studies, then phase 2 studies looking for efficacy in patients with either newly presenting or relapsed leptomeningeal [73, 86, 94, 95, 97, 146] disease will be necessary. Once a drug has been assessed as effective by intermittent or infusional techniques of IT administration, then phase 3 trials to evaluate its clinical effectiveness or preparation of sustained release formulation for intermittent IT administration would be justified. The preparatory clinical testing can only be developed within centres with the relevant neuroscience/pharmaceutical/pharmacological research expertise.
Conclusion
This review has extended the list of candidate agents suitable for further investigation of intrathecal treatment of leptomeningeal medulloblastoma. It has identified the importance of making basic physicochemical criteria available to the academic domain by pharma and academic research groupings in order to accelerate the development of new cancer agents. It has highlighted the opportunity to replicate the success of CNS targeting of drug therapy in leukaemia and lymphoma, by proposing trials of novel intrathecal chemotherapy in medulloblastoma. It has identified the need to establish an acceptable process for selecting new drugs for trial and a suitable trial design. 
